Home/Pipeline/Rinri Therapeutics Collaboration

Rinri Therapeutics Collaboration

Sensorineural Hearing Loss

Pre-clinical/ClinicalActive

Key Facts

Indication

Sensorineural Hearing Loss

Phase

Pre-clinical/Clinical

Status

Active

Company

Mytos

About Mytos

Mytos is an automated CDMO for regenerative medicine, leveraging its iDEM™ automation platform to reduce the cost and labor of cell therapy manufacturing. The company targets the critical bottleneck of scalable production for clinical-stage biotechs, offering a 'one-stop-shop' from process development to regulatory support. Backed by over $24M in funding and strategic partnerships with organizations like the CGT Catapult, Mytos aims to make curative cell therapies commercially viable and widely accessible.

View full company profile

Therapeutic Areas

Parkinson's Disease Sensorineural Hearing Loss Corneal Blindness Bone Fractures

Other Sensorineural Hearing Loss Drugs

Drug	Company	Phase	Status
Lead Cell Therapy Program	Rinri Therapeutics	Phase 1	Active
LY3885125 (AK-OTOF)	Eli Lilly	Phase 1/2	Active
ANP1	Lineage Cell Therapeutics	Preclinical	Active